LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes

Recent biochemical observations have helped redefine antigenic components within the voltage-gated potassium channel (VGKC) complex. The related autoantibodies may be now divided into likely pathogenic entities, which target the extracellular domains of leucine-rich glioma-inactivated 1 (LGI1) and c...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Binks, S, Klein, C, Waters, P, Pittock, S, Irani, S
Format:	Journal article
Wydane:	BMJ Publishing Group 2017

Podobne zapisy

The immunogenetics of LGI1- and CASPR2-antibody encephalitis: towards aetiology
od: Binks, S
Wydane: (2022)

Distinct HLA associations of LGI1 and CASPR2-antibody diseases
od: Binks, S, i wsp.
Wydane: (2018)

Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis
od: Kelly, MJ, i wsp.
Wydane: (2024)

CXCL13 levels in LGI1-and CASPR2-autoantibody syndromes
od: Michael, S, i wsp.
Wydane: (2019)

Immunotherapy responsive neuropathic pain associated with LGI1 and CASPR2 antibodies
od: Ramanathan, S, i wsp.
Wydane: (2021)

Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2
od: Michael, S, i wsp.
Wydane: (2020)

Phenotypic Spectrum of CASPR2 and LGI1 Antibodies Associated Neurological Disorders in Children
od: Yan Jiang, i wsp.
Wydane: (2022-04-01)

Hippocampal epileptogenesis in LGI1, CASPR2 and GABABR antibodies: preliminary findings
od: Romoli, M, i wsp.
Wydane: (2020)

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy
od: Dubey, D, i wsp.
Wydane: (2019)

Randomized placebo‐controlled trial of intravenous immunoglobulin in autoimmune LGI1/CASPR2 epilepsy
od: Dubey, D, i wsp.
Wydane: (2019)

The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis
od: Goevert, F, i wsp.
Wydane: (2019)

Contactin-2 associated protein (CASPR2) autoimmune neurological conditions: Detailed clinical phenotype and antibody quantification
od: Varley, J, i wsp.
Wydane: (2017)

Vgkc is dead: long live lgi1- and caspr2-antibodies. intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies
od: Lang, B, i wsp.
Wydane: (2017)

Combining clinical and molecular heterogeneity within CASPR2-antibody mediated diseases: towards the underlying disease biology
od: Binks, S, i wsp.
Wydane: (2020)

LGI1 and CASPR2-related Morvan syndrome - diagnostic challenges in a pediatric case
od: Elena Catalina Petrov, i wsp.
Wydane: (2023-06-01)

Caspr2 antibodies in patients with thymomas.
od: Vincent, A, i wsp.
Wydane: (2010)

Isaacs Syndrome in A Patient with Positive CASPR2 And LGI1 Antibodies: A Case Report and Literature Review
od: Rasa Zafari, i wsp.
Wydane: (2024-04-01)

Mechanisms of disease perpetuation and pathogenesis in autoantibody-mediated epilepsies with a focus on LGI1- and CASPR2-related syndromes
od: Michael, S
Wydane: (2022)

Hemichorea Associated with CASPR2 Antibody
od: Iryna Vynogradova, i wsp.
Wydane: (2014-05-01)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
od: Jang, Y, i wsp.
Wydane: (2018)

Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis
od: Susann Ludewig, i wsp.
Wydane: (2023-01-01)

Reply to: Hemichorea Associated with CASPR2 Antibody
od: Ritesh A. Ramdhani, i wsp.
Wydane: (2014-05-01)

Cognitive, neuropsychiatric and quality-of-life sequelae in LGI1-antibody disease demonstrates fatigue as the key determinant of wellbeing
od: Binks, S, i wsp.
Wydane: (2020)

Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.
od: Irani, SR, i wsp.
Wydane: (2011)

‘Less contented as a person’: preliminary data from the LGI1-QoL study
od: Binks, S, i wsp.
Wydane: (2017)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
od: Yoonhyuk Jang, i wsp.
Wydane: (2018-09-01)

CASPR2 antibody associated neurological syndromes in children
od: Liwen Wu, i wsp.
Wydane: (2023-02-01)

‘Less contented as a person’: an update from the LGI1-QoL study
od: Binks, S, i wsp.
Wydane: (2019)

Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.
od: Tofaris, G, i wsp.
Wydane: (2012)

Intrathecal B cell activation in LGI1-antibody encephalitis
od: Lehmann-Horn, K, i wsp.
Wydane: (2020)

LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures
od: Aurangzeb, S, i wsp.
Wydane: (2017)

Investigating B cell biology in CASPR2-antibody encephalitis
od: Sun, B
Wydane: (2022)

Efficacy of Tocilizumab in Limbic Encephalitis with Anti-CASPR2 Antibodies
od: Maurizio Benucci, i wsp.
Wydane: (2020-01-01)

CXCL13 levels and autoantibody epitope specificities in LGI1-autoantibody syndromes
od: Michael, S, i wsp.
Wydane: (2019)

LGI1-antibody associated epilepsy successfully treated in the outpatient setting
od: Uribe-San-Martín, R, i wsp.
Wydane: (2020)

Clonal hematopoiesis in LGI1‐antibody encephalitis
od: Soo Jean Shin, i wsp.
Wydane: (2024-10-01)

Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis
od: Irani, SR
Wydane: (2021)

Antibodies to the Caspr1/contactin-1 complex in chronic inflammatory demyelinating polyneuropathy
od: Pascual-Goni, E, i wsp.
Wydane: (2021)

CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
od: Gelfand, JM, i wsp.
Wydane: (2022)

Characterization of cardiac bradyarrhythmia associated with LGI1-IgG autoimmune encephalitis
od: Hannah H. Zhao-Fleming, i wsp.
Wydane: (2022-10-01)